-
Electronic (PDF)
-
Site License
-
Enterprisewide
Neuropathic Pain - Pipeline Review, H1 2012
Global Markets Direct, February 2012, Pages: 275
Neuropathic Pain – Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Neuropathic Pain - Pipeline Review, H1 2012', provides an overview of the Neuropathic Pain therapeutic pipeline. This report provides information on the therapeutic development for Neuropathic Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuropathic Pain. 'Neuropathic Pain - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Neuropathic Pain.
- A review of the Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Neuropathic Pain pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Neuropathic Pain.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Neuropathic Pain pipeline depth and focus of Neuropathic Pain therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords
Neuropathic Pain Therapeutic Products under Development, Key Players in Neuropathic Pain Therapeutics, Neuropathic Pain Pipeline Overview, Neuropathic Pain Pipeline, Neuropathic Pain Pipeline Assessment
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neuropathic Pain Overview
Therapeutics Development
An Overview of Pipeline Products for Neuropathic Pain
Neuropathic Pain Therapeutics under Development by Companies
Neuropathic Pain Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Neuropathic Pain Therapeutics – Products under Development by Companies
Neuropathic Pain Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Neuropathic Pain Therapeutics Development
Bristol-Myers Squibb Company
Genzyme Corporation
Kyowa Hakko Kirin Co., Ltd.
Abbott Laboratories
Biogen Idec Inc.
Allergan, Inc.
NsGene A/S
Valeant Pharmaceuticals International
Sanofi-Aventis
AstraZeneca PLC
GlaxoSmithKline plc
Nektar Therapeutics
Quark Pharmaceuticals, Inc.
Dainippon Sumitomo Pharma Co., Ltd.
Sangamo BioSciences, Inc.
XenoPort, Inc.
BioLineRx, Ltd.
Astellas Pharma Inc.
Daewoong Pharmaceutical Co., Ltd.
Eisai Co., Ltd.
Glenmark Pharmaceuticals Ltd.
Orion Corporation
Pfizer Inc.
Purdue Pharma L.P.
EpiCept Corporation
Evotec Aktiengesellschaft
GW Pharmaceuticals plc
Anavex Life Sciences Corp.
IntelGenx Technologies Corp.
AVANIR Pharmaceuticals
Lpath, Inc.
Medivir AB
Benitec Ltd.
NeurogesX, Inc.
NicOx SA
NPS Pharmaceuticals, Inc.
Nuvo Research Inc.
Pharmos Corporation
CombinatoRx, Incorporated
Torrent Pharmaceuticals Limited
SCOLR Pharma, Inc.
Neurim Pharmaceuticals (1991) Ltd.
Pluristem Therapeutics Inc.
DARA BioSciences, Inc.
Newron Pharmaceuticals S.p.A.
Debiopharm Group
D-Pharm Ltd.
Auspex Pharmaceuticals
VistaGen Therapeutics , Inc.
Palau Pharma S.A
Snowdon Inc.
Neurotune AG
Xenon Pharmaceuticals Inc.
CREABILIS Therapeutics S.r.l.
Amura Holdings Ltd.
Affectis Pharmaceuticals AG
PharmEste
Pharmascience Inc.
Arcion Therapeutics, Inc.
Rottapharm SpA
WEX Pharmaceuticals Inc.
Hydra Biosciences, Inc.
Yaupon Therapeutics, Inc.
NeurAxon, Inc.
Virobay Inc.
Concert Pharmaceuticals, Inc.
QRxPharma Limited
Cara Therapeutics, Inc.
Bial Group
KYORIN Pharmaceutical Co., Ltd.
KAI Pharmaceuticals Inc.
Winston Pharmaceuticals, Inc.
Spinifex Pharmaceuticals Pty Limited
TheraQuest Biosciences, LLC
RaQualia Pharma Inc.
Mt Cook Pharma. Inc.
SK Bio-Pharmaceuticals
Naurex, Inc.
Cytogel Pharma, LLC
Neuropathic Pain – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
E2007 - Drug Profile
AZD2066 - Drug Profile
Lyrica - Drug Profile
AZD2423 - Drug Profile
Horizant - Drug Profile
AVP-923 - Drug Profile
AVP-923 - Drug Profile
Axomadol - Drug Profile
Sativex - Drug Profile
NT-11624 - Drug Profile
Debio 0827 - Drug Profile
Stedesa - Drug Profile
Carisbamate - Drug Profile
Eladur - Drug Profile
KRN5500 - Drug Profile
MN-166 - Drug Profile
NGX-1998 - Drug Profile
AmiKet - Drug Profile
Tectin - Drug Profile
Topical XEN402 - Drug Profile
Neurotropin - Drug Profile
Ralfinamide - Drug Profile
Oxycodone + Pregabalin - Drug Profile
Civamide Patch - Drug Profile
KAI-1678 - Drug Profile
GRT6005 - Drug Profile
AEG33773 - Drug Profile
EHT/AGN 0001 - Drug Profile
Ketamine - Drug Profile
YKP3089 - Drug Profile
Marijuana - Drug Profile
Marijuana - Drug Profile
Amitriptyline - Drug Profile
Pregabalin - Drug Profile
Lidocaine - Drug Profile
Lidocaine Patch - Drug Profile
Losmapimod - Drug Profile
Pregabalin - Drug Profile
Pregabalin - Drug Profile
Amitriptyline + Ketamine + Lidocaine - Drug Profile
Sativex - Drug Profile
Etoricoxib - Drug Profile
AGN-214868 - Drug Profile
Gabapentin + Donepezil - Drug Profile
Gabapentin + Venlafaxine - Drug Profile
Paxil - Drug Profile
Duloxetine + Methadone - Drug Profile
Plasmid VEGF Gene Transfer - Drug Profile
Ketamine - Drug Profile
ATx09-002 - Drug Profile
Gabapentin - Drug Profile
DWP05195 - Drug Profile
Retigabine - Drug Profile
XPF-002 - Drug Profile
Intravenous immunoglobulin + Normal Saline - Drug Profile
Intravenous immunoglobulin + Normal Saline - Drug Profile
Varicella-Zoster Vaccine - Drug Profile
Ketamine - Drug Profile
Nabilone - Drug Profile
EMA401 - Drug Profile
Botox - Drug Profile
CNSB015 - Drug Profile
BMS-954561 - Drug Profile
Versatis - Drug Profile
ATx08-001 - Drug Profile
Oral XEN402 - Drug Profile
Milnacipran - Drug Profile
ABT-639 - Drug Profile
ARC 2022 - Drug Profile
CNV1014802 - Drug Profile
Methadone Hydrochloride - Drug Profile
Neuropathic Pain Therapeutics – Drug Profile Updates
Neuropathic Pain Therapeutics – Discontinued Products
Neuropathic Pain Therapeutics - Dormant Products
Neuropathic Pain – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Neuropathic Pain, H1 2012
Products under Development for Neuropathic Pain – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Development by Companies, H1 2012 (Contd..3)
Number of Products under Development by Companies, H1 2012 (Contd..4)
Number of Products under Development by Companies, H1 2012 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Development by Companies, H1 2012 (Contd..2)
Products under Development by Companies, H1 2012 (Contd..3)
Products under Development by Companies, H1 2012 (Contd..4)
Products under Development by Companies, H1 2012 (Contd..5)
Products under Development by Companies, H1 2012 (Contd..6)
Products under Development by Companies, H1 2012 (Contd..7)
Products under Development by Companies, H1 2012 (Contd..8)
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Bristol-Myers Squibb Company, H1 2012
Genzyme Corporation, H1 2012
Kyowa Hakko Kirin Co., Ltd., H1 2012
Abbott Laboratories, H1 2012
Biogen Idec Inc., H1 2012
Allergan, Inc., H1 2012
NsGene A/S, H1 2012
Valeant Pharmaceuticals International, H1 2012
Sanofi-Aventis, H1 2012
AstraZeneca PLC, H1 2012
GlaxoSmithKline plc, H1 2012
Nektar Therapeutics, H1 2012
Quark Pharmaceuticals, Inc., H1 2012
Dainippon Sumitomo Pharma Co., Ltd., H1 2012
Sangamo BioSciences, Inc., H1 2012
XenoPort, Inc., H1 2012
BioLineRx, Ltd., H1 2012
Astellas Pharma Inc., H1 2012
Daewoong Pharmaceutical Co., Ltd., H1 2012
Eisai Co., Ltd., H1 2012
Glenmark Pharmaceuticals Ltd., H1 2012
Orion Corporation, H1 2012
Pfizer Inc., H1 2012
Purdue Pharma L.P., H1 2012
EpiCept Corporation, H1 2012
Evotec Aktiengesellschaft, H1 2012
GW Pharmaceuticals plc, H1 2012
Anavex Life Sciences Corp., H1 2012
IntelGenx Technologies Corp., H1 2012
AVANIR Pharmaceuticals, H1 2012
Lpath, Inc., H1 2012
Medivir AB, H1 2012
Benitec Ltd., H1 2012
NeurogesX, Inc., H1 2012
NicOx SA, H1 2012
NPS Pharmaceuticals, Inc., H1 2012
Nuvo Research Inc., H1 2012
Pharmos Corporation, H1 2012
CombinatoRx, Incorporated, H1 2012
Torrent Pharmaceuticals Limited, H1 2012
SCOLR Pharma, Inc., H1 2012
Neurim Pharmaceuticals (1991) Ltd., H1 2012
Pluristem Therapeutics Inc., H1 2012
DARA BioSciences, Inc., H1 2012
Newron Pharmaceuticals S.p.A., H1 2012
Debiopharm Group, H1 2012
D-Pharm Ltd., H1 2012
Auspex Pharmaceuticals, H1 2012
VistaGen Therapeutics , Inc., H1 2012
Palau Pharma S.A, H1 2012
Snowdon Inc., H1 2012
Neurotune AG, H1 2012
Xenon Pharmaceuticals Inc., H1 2012
CREABILIS Therapeutics S.r.l., H1 2012
Amura Holdings Ltd., H1 2012
Affectis Pharmaceuticals AG, H1 2012
PharmEste, H1 2012
Pharmascience Inc., H1 2012
Arcion Therapeutics, Inc., H1 2012
Rottapharm SpA, H1 2012
WEX Pharmaceuticals Inc., H1 2012
Hydra Biosciences, Inc., H1 2012
Yaupon Therapeutics, Inc., H1 2012
NeurAxon, Inc., H1 2012
Virobay Inc., H1 2012
Concert Pharmaceuticals, Inc., H1 2012
QRxPharma Limited, H1 2012
Cara Therapeutics, Inc., H1 2012
Bial Group, H1 2012
KYORIN Pharmaceutical Co., Ltd., H1 2012
KAI Pharmaceuticals Inc., H1 2012
Winston Pharmaceuticals, Inc., H1 2012
Spinifex Pharmaceuticals Pty Limited, H1 2012
TheraQuest Biosciences, LLC, H1 2012
RaQualia Pharma Inc., H1 2012
Mt Cook Pharma. Inc., H1 2012
SK Bio-Pharmaceuticals, H1 2012
Naurex, Inc., H1 2012
Cytogel Pharma, LLC, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Neuropathic Pain Therapeutics – Drug Profile Updates
Neuropathic Pain Therapeutics – Discontinued Products
Neuropathic Pain Therapeutics – Discontinued Products (Contd..1)
Neuropathic Pain Therapeutics – Discontinued Products (Contd..2)
Neuropathic Pain Therapeutics – Discontinued Products (Contd..3)
Neuropathic Pain Therapeutics – Discontinued Products (Contd..4)
Neuropathic Pain Therapeutics – Dormant Products
Neuropathic Pain Therapeutics – Dormant Products (Contd..1)
Neuropathic Pain Therapeutics – Dormant Products (Contd..2)
Neuropathic Pain Therapeutics – Dormant Products (Contd..3)
Neuropathic Pain Therapeutics – Dormant Products (Contd..4)
Neuropathic Pain Therapeutics – Dormant Products (Contd..5)
Neuropathic Pain Therapeutics – Dormant Products (Contd..6)
List of Figures
Number of Products under Development for Neuropathic Pain, H1 2012
Products under Development for Neuropathic Pain – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
